Browse the evidence

The physiological mechanism of diabetes remission via weight loss involves the reduction of ectopic fat in the liver and pancreas, which restores beta-cell function and insulin sensitivity.

N/A (Mechanistic explanation).

Weight loss of 5-10% significantly improves reproductive outcomes (ovulation, menstrual regularity) and metabolic markers (insulin resistance, lipids) in women with PCOS, regardless of the specific dietary composition used to achieve the weight loss.

Aim for a 5-10% reduction in body weight through a moderate energy deficit (500-750 kcal/day). You do not need to follow a specific restrictive diet (like low-carb or low-fat) to see benefits; any dietary approach that helps you achieve this weight loss will improve insulin resistance, lipids, and reproductive health.

Visceral Adipose Tissue (VAT) and Epicardial Adipose Tissue (EAT) are stronger predictors of incident HFpEF and mortality than Body Mass Index (BMI) alone.

Don't just look at your weight. For heart failure risk, where you store fat matters more. High belly fat (VAT) and heart-adjacent fat (EAT) are major risks, even if your overall weight seems okay. Imaging can help assess this risk.

Adult obesity and overweight significantly increase the odds of PCOS, with adolescents showing even higher odds than adults for the same degree of adiposity.

Maintaining a healthy weight in adulthood reduces PCOS risk, but adolescent weight is even more critical. Adolescents with overweight or obesity face higher odds of developing PCOS than adults with the same conditions. Prioritize healthy weight management during teenage years.

Obesity results from a complex interaction between environmental factors (e.g., ultra-processed foods, reduced physical activity) and genetic susceptibility, rather than environmental factors alone.

Recognize that your genetics may predispose you to weight gain, but this does not mean you are powerless. Understanding this interaction can help you adopt more effective, personalized strategies for managing your weight, such as working with healthcare providers on targeted interventions.

Obesity is a significant risk factor for respiratory diseases, including obstructive sleep apnea (OSA), obesity hypoventilation syndrome (OHS), and asthma, primarily due to mechanical effects on lung volume and airway collapse.

If you have obesity, you are at higher risk for sleep apnea and breathing problems. Excess weight can narrow your airways and reduce lung capacity. Losing weight can help improve breathing and reduce the severity of conditions like asthma and sleep apnea.

Visceral adipose tissue accumulation is a primary risk factor for cardiometabolic disease, whereas subcutaneous fat is metabolically neutral or healthy.

Not all fat is created equal. Visceral fat (around your organs) is dangerous and increases your risk of diabetes and heart disease. Subcutaneous fat (under your skin) is less harmful. Focus on reducing visceral fat through diet and exercise, as this has the biggest impact on your metabolic health.

Bariatric surgery (e.g., Roux-en-Y gastric bypass, sleeve gastrectomy) is an effective treatment for obesity and T2DM, capable of inducing remission of diabetes through both weight-loss-dependent and weight-loss-independent mechanisms.

Bariatric surgery is a powerful tool for treating obesity and Type 2 Diabetes. It can lead to diabetes remission (normal blood sugar without meds) through both weight loss and hormonal changes. It is invasive and carries risks like nutrient deficiencies, so it requires lifelong medical monitoring.

Visceral Adipose Tissue (VAT) and ectopic fat deposition are causal drivers of cardiometabolic disease, whereas subcutaneous fat (specifically gluteofemoral adipose tissue, GFAT) is protective, independent of total body weight.

Focus on preserving subcutaneous fat storage capacity (especially in hips/thighs) and reducing visceral/abdominal fat. This is achieved through diet quality and physical activity, not just weight loss. If you have a 'skinny fat' phenotype (normal weight but high visceral fat), your risk is high. If you have a 'healthy obese' phenotype (high weight but low visceral fat and good metabolism), your risk may be lower than expected.

High-carbohydrate overfeeding increases 24-hour energy expenditure (EE) more than high-fat or fasting diets, despite being associated with lower lipid oxidation.

If you are overfeeding, a high-carbohydrate diet may result in higher total energy expenditure than a high-fat diet. This does not mean high-carb is better for weight loss, but it does show that the body burns more total energy when processing high carbs in an overfed state.

Semaglutide reduced major adverse cardiovascular events and all-cause mortality.

Semaglutide may be recommended for patients at risk of cardiovascular events.

No serious adverse events were reported during the trial.

TRE and CR appear to be safe dietary strategies for weight loss in this population.

Tirzepatide showed a favourable safety profile, without increasing the risk of serious adverse events or impacting mortality rates.

Tirzepatide can be used safely in obesity management without significant risk of serious side effects.

Lean mass constituted 25%–39% of total weight lost with incretin agonists: semaglutide (35.2%), tirzepatide (25.4%), and liraglutide (26.8%).

Incretin therapies can lead to significant lean mass loss during weight reduction.

Lifestyle interventions showed comparable proportional lean mass loss (26.2%) to incretin therapies (p = 0.42 for comparison).

Lifestyle interventions can be as effective as incretin therapies in preserving lean mass during weight loss.

NAFLD is a risk factor for atherosclerotic cardiovascular disease.

Clinicians should consider NAFLD when assessing cardiovascular risk in patients.

Obesity has been declared a disease that results in impaired quality of life and reduced life expectancy.

Healthcare practitioners should recognize obesity as a disease and address its impact on patients' quality of life.

Two-thirds of obesity-related excess mortality is attributable to cardiovascular disease.

Efforts to reduce obesity should be prioritized to decrease cardiovascular disease mortality.

Obesity is underrecognized and sub-optimally addressed compared to other modifiable cardiovascular risk factors.

Clinicians should enhance their focus on obesity as a critical cardiovascular risk factor.

High-quality meta-evidence supports the association between total UPF consumption and higher T2D risk.

Practitioners should consider the quality of evidence when advising on dietary choices related to UPF.

Common variables in definitions of sarcopenia include appendicular lean soft tissue mass, grip strength, and gait speed.

Understanding these variables can help practitioners assess sarcopenia more effectively.

Food insecurity is a common cause of inadequate dietary intake.

Addressing food insecurity is crucial for improving dietary intake.

Higher sitting time (≥8 hours per day) is associated with an increased risk of all-cause mortality (HR, 1.20; 95% CI, 1.10-1.31) and major cardiovascular disease (HR, 1.21; 95% CI, 1.10-1.34).

Reducing sitting time to less than 8 hours per day may lower the risk of mortality and cardiovascular events.

The association of sitting time with the composite outcome is stronger in low-income and lower-middle-income countries (HR, 1.29; 95% CI, 1.16-1.44) compared to high-income and upper-middle-income countries (HR, 1.08; 95% CI, 0.98-1.19).

Public health strategies should focus on reducing sitting time, especially in low-income countries.